Leading pharmaceutical manufacturer, Aesica, has experienced significant growth in the US market during 2011 and is targeting further expansion this year with plans to acquire manufacturing sites in North America to support its continued evolution.
The last 12 months have seen the company achieve significant sales in the US, bolstered by increased demand for both commercial and development scale APIs from large pharma and emerging biotechnology companies across America.
The company’s long-term vision is to be the number one supplier of Active Pharmaceutical Ingredients and Formulated Products to the pharmaceutical industry. Aesica has always believed this vision will be achieved through a combination of organic growth and strategic acquisitions.
Aesica plans to establish sites and assets in North America this year which will enhance its capabilities in API production and Formulation Development in the region. The expansion will enable the company to focus on developing its custom synthesis offering for the North American market and follows a succession of strategic acquisitions in Europe as Aesica bolstered its global manufacturing presence in 2011 with acquisitions in Germany and Italy.
Dr. Robert Hardy, Chief Executive, Aesica, said:
“Expanding the Aesica brand further into the US market is an integral part of our long-term strategic plan, therefore our strong sales figures for 2011 are extremely encouraging. It lays a solid foundation for the company to establish manufacturing sites this year, which will enable us to build on the successes of our business development teams based in our east and west coast offices and provide a more localized service offering. Since Aesica started business in 2004 we have quadrupled in size. In the last twelve months we doubled the size of our workforce. This is all part of our vision to become the preferred CMO in the industry and a trusted partner in the US.”
Aesica is a leading full-service provider of development and manufacturing services for Formulated Products and Active Pharmaceutical Ingredients. The company develops long-term strategic partnerships with its clients to help them deliver value into the market place.